Format: Multi-part training (online, residential, experiential, and supervised components)
Provider: Multidisciplinary Association for Psychedelic Studies (MAPS)
Certification: MAPS Certificate of Completion (required to provide MDMA-assisted psychotherapy at approved sites)
Eligibility: Licensed clinicians or trainees in an approved clinical program
Post-traumatic Stress Disorder (PTSD) remains one of the most challenging conditions to treat, with many people continuing to experience distress even after standard therapies. MDMA-assisted psychotherapy is emerging as a groundbreaking approach, offering renewed hope for individuals whose symptoms have not improved with traditional methods. As this treatment moves toward broader approval, the need for clinicians trained to deliver it safely and effectively is growing rapidly.
Our next training event is not yet scheduled. Be the first to know when registration opens! Simply register below, and we’ll notify you as soon as details become available.
The Multidisciplinary Association for Psychedelic Studies (MAPS) offers a comprehensive, multi-part training program designed to prepare therapists to deliver MDMA-assisted psychotherapy with skill, compassion, and cultural sensitivity. All Behavioural Wellness Clinic therapists providing MDMA-assisted therapy are either fully certified or actively completing this program.
Over eight to nine sessions, you’ll engage in a blend of structured teaching, group interaction, and reflective practice. Each week introduces a theme designed to stretch your skills and expand your understanding of the therapeutic relationship. Topics include advanced functional analysis, using awareness and courage to address vulnerability, and cultivating therapeutic love as a powerful intervention.
By the end of this training, you will:
A foundational course covering the chemistry and history of MDMA, treatment protocols, common reactions, and research evidence drawn from the MAPS Treatment Manual and related literature.
An intensive in-person training featuring video review, live dialogue with experienced MDMA therapists, and instruction on session structure, cultural considerations, and PTSD diagnosis within psychedelic-assisted care.
Trainees participate in an FDA-approved clinical trial (MT-2) modeled on the MDMA-assisted psychotherapy protocol. This includes preparatory sessions, an 8-hour MDMA session, integration sessions, and supervised practicum alongside an experienced therapy team.
Structured role-playing exercises allow trainees to practice therapeutic interactions as provider, participant, and observer, with feedback provided through live or recorded review.
Following initial training, clinicians receive detailed supervision and adherence-based feedback during their first clinical cases. Successful completion leads to MAPS certification and eligibility to deliver MDMA-assisted psychotherapy at approved sites.